TABLE 3.
The incidence of adverse events and treatment cessation relative to the CCI risk score
| CCI 2 | CCI 3 | CCI ≥ 4 | P‐value | |
|---|---|---|---|---|
| Entire cohort | ||||
| Number of patients (n = 452) | 353 (78.1) | 72 (15.9) | 27 (6.0) | |
| Hematological AEs (at any grade) | 88 (24.9) | 18 (25.0) | 7 (25.9) | .99 |
| Hematological AEs (at grade 3 to 4) | 23 (6.5) | 6 (8.3) | 3 (11.1) | .60 |
| Non‐hematological AEs (at any grade) | 113 (32.0) | 20 (27.8) | 12 (44.4) | .29 |
| Non‐hematological AEs (at grade 3 to 4) | 18 (5.1) | 1 (1.4) | 5 (18.5) | <.01 |
| VAE (at any grade) | 8 (2.3) | 3 (4.2) | 1 (3.7) | .62 |
| TKI cessation | 42 (11.9) | 16 (22.2) | 9 (33.3) | <.01 |
| Imatinib cohort | ||||
| Number of patients (n = 139) | 96 (69.1) | 34 (24.5) | 9 (6.4) | |
| Hematological AEs (at any grade) | 5 (5.2) | 4 (11.8) | 3 (33.3) | .01 |
| Hematological AEs (at grade 3 to 4) | 1 (1.0) | 3 (8.8) | 3 (33.3) | <.01 |
| Non‐hematological AEs (at any grade) | 9 (9.4) | 3 (8.8) | 3 (33.3) | .08 |
| Non‐hematological AEs (at grade 3 to 4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NE |
| TKI cessation | 16 (16.7) | 6 (17.6) | 3 (33.3) | .46 |
| 2GTKI cohort | ||||
| Number of patients (n = 313) | 257 (82.1) | 38 (12.1) | 18 (5.8) | |
| Hematological AEs (at any grade) | 83 (32.3) | 14 (36.8) | 4 (22.2) | .56 |
| Hematological AEs (at grade 3 to 4) | 22 (8.6) | 3 (7.9) | 1 (5.6) | .90 |
| Non‐hematological AEs (at any grade) | 104 (40.5) | 17 (44.7) | 9 (50.0) | .67 |
| Non‐hematological AEs (at grade 3 to 4) | 18 (7.0) | 1 (2.6) | 5 (27.8) | <.01 |
| TKI cessation | 26 (10.1) | 10 (26.3) | 6 (33.3) | .001 |
Adverse events were graded according to the Common Toxicity Criteria of the Common Toxicity Criteria of the National Cancer Institute (NCI‐CTC) version 4.03.
Abbreviations: 2GTKI, second‐generation tyrosine kinase inhibitor; AEs, adverse events; CCI, Charlson Comorbidity Index; NE, not estimable; TKI, tyrosine kinase inhibitor; VAE, vascular adverse event.